Shares of Novartis AG (VTX:NOVN) have earned an average recommendation of “Hold” from the fourteen research firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is CHF 89.71.

A number of equities analysts have recently issued reports on NOVN shares. Goldman Sachs Group set a CHF 105 price target on Novartis and gave the stock a “buy” rating in a research note on Monday, July 29th. Morgan Stanley set a CHF 83 price target on Novartis and gave the stock a “sell” rating in a research note on Thursday, May 30th. Credit Suisse Group set a CHF 88 price target on Novartis and gave the stock a “neutral” rating in a research note on Friday, July 19th. Jefferies Financial Group set a CHF 95 price target on Novartis and gave the stock a “buy” rating in a research note on Thursday, May 16th. Finally, HSBC set a CHF 88 price target on Novartis and gave the stock a “neutral” rating in a research note on Monday, July 22nd.

Novartis has a 52 week low of CHF 72.45 and a 52 week high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

See Also: Net Asset Value

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.